24/7 Market News Snapshot 22 September, 2025 – Strata Skin Sciences, Inc. Common Stock (NASDAQ:SSKN)

September 22, 2025

DENVER, Colo., 22 September, 2025 (www.247marketnews.com) – (NASDAQ:SSKN) are discussed in this article.
Strata Skin Sciences, Inc. (SSKN) is experiencing positive momentum in the financial markets, with shares trading at $1.719, reflecting a 9.49% increase from the previous close of $1.570 during the pre-market session. This strong performance is supported by a significant trading volume of 2.17 million shares, indicating robust investor interest. Key technical analysis suggests critical support at approximately $1.570 and potential resistance around $1.800. Continuous buying activity could facilitate a breakthrough of this resistance level, further enhancing bullish sentiment. Analysts recommend closely monitoring key indicators, such as the relative strength index (RSI) and moving averages, to gauge the stock’s future direction.

In tandem with its stock performance, Strata has announced the publication of a pivotal study in the International Journal of Dermatology, which evaluates the efficacy of its 308nm Excimer Laser in conjunction with oral Janus kinase (JAK) inhibitors for the treatment of localized non-segmental vitiligo. The study, conducted with 251 participants, highlighted a 14.20% increase in repigmentation rates with the combination therapy, which outperformed monotherapy options. Over a 52-week period, the combination treatment achieved a significant efficacy rate of 100%, with 96.5% of patients maintaining pigmentation stability one year post-treatment and a low relapse rate of 8.8%.

Dr. Dolev Rafaeli, CEO of Strata, emphasized the significance of these results, stating, “This study underscores the sustained interest in our Excimer laser technology and the substantial benefits of combination therapy.” The data supports Strata’s strategic initiatives to broaden reimbursement avenues for treating various skin conditions beyond vitiligo, solidifying the company’s leadership in dermatological innovation. With an impressive archive of over 400 peer-reviewed studies, Strata is dedicated to enhancing patient outcomes through pioneering treatments, anticipating broader market access for these advancements by early 2026.

Related news for (SSKN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.